ReviewBest practice & research. Clinical rheumatology2026
Gastrointestinal involvement in systemic sclerosis: A spotlight on small bowel involvement, complications and management.
Review in Best practice & research. Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systemic sclerosis and small bowel involvement: A systematic review of diagnostic approaches and current evidence.Seminars in arthritis and rheumatism · 2026Pooled it
- [Gastrointestinal manifestations in idiopathic inflammatory myopathies : Dysphagia, intestinal vasculopathy and pneumatosis cystoides intestinalis].Zeitschrift fur Rheumatologie · 2026Review
- Proteome-wide serology reveals immune-defined subtypes of gastrointestinal disease in systemic sclerosis.bioRxiv : the preprint server for biology · 2026Article
- PPI-Refractory GERD in Systemic Sclerosis Is Driven by Distinct Esophageal and Gastric Motility Abnormalities.medRxiv : the preprint server for health sciences · 2026Article
- Biomarker patterns across skin-lung-gut burden in systemic sclerosis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Small-bowel involvement in systemic sclerosis is frequent but often underdiagnosed, largely due to the lack of standardized diagnostic protocols for its evaluation. Small bowel dysmotility manifests with symptoms such as abdominal pain, diarrhea, bloating, and distension, and complications including small intestinal bacterial overgrowth, reduced oral intake, malnutrition, and, in severe cases, intestinal pseudo-obstruction. These complications are associated with significant morbidity, dependence on parenteral nutrition, and poor prognosis. In this review, we summarize the current evidence on the pathogenesis, diagnosis, and management of small-bowel involvement, with a focus on advances in understanding autoimmune neuromuscular mechanisms and their clinical and serological correlates. We discuss diagnostic approaches and propose a structured, multidisciplinary treatment strategy integrating nutritional optimization, targeted prokinetic and antibiotic therapy, and management of acute pseudo-obstructive crises. Finally, we highlight future directions, including the development of biomarkers, advanced motility assessments, and novel therapeutic approaches aimed at earlier diagnosis and personalized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.